Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03958071 · ClinicalTrials.gov registry record
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 13,264
- Enrollment target
- 1
- Study location
NCT03958071: Completed study of Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.
NCT03958071 is a study of Idiopathic Pulmonary Fibrosis that has completed, run by Boehringer Ingelheim. The registered enrollment target is 13,264 participants, above the 491-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (2601% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03958071, a study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 13,264 participants
- Enrollment target
- 1
- Study location
Study Summary
To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
Primary Outcome
IQVIA's GE Centricity Electronic medical records database was used for this study. This is an anonymized Health Insurance Portability and Accountability Act of 1996 (HIPPA) compliant database populated with patient data from ambulatory care records. The patient characteristic age for Idiopathic Pulmonary Fibrosis (IPF) patients at 12-month pre-treatment (baseline) was compared between each of the cohorts (nintedanib vs. pirfenidone, nintedanib vs. untreated, pirfenidone vs. untreated), differen
Conditions Studied
Interventions
- DRUG Pirfenidone
- DRUG Nintedanib
- OTHER Untreated Cohort
Study Locations (1)
Pennsylvania
- Plymouth Meeting - Plymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,264 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2019-05-31 |
What the finished NCT03958071 record still lists
NCT03958071 is an observational study that tracks outcomes without assigning an intervention. Its 13,264 participants enrollment target places it among the larger protocols in the corpus, above the 491-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (2601% higher).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Pirfenidone is the first listed.
NCT03958071 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03958071 about?
NCT03958071 is a clinical study titled "A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking". To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
What is the current status of trial NCT03958071?
This trial is currently completed. The enrollment target is 13,264 participants. The study started on 2019-02-01. Estimated completion is 2019-05-31.
What conditions does trial NCT03958071 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT03958071?
The interventions under investigation include: Pirfenidone (DRUG), Nintedanib (DRUG), Untreated Cohort (OTHER).
Who is sponsoring clinical trial NCT03958071?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03958071 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03958071's enrollment target sits among peer trials
13,264 1st of 51 higher than 51 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI